This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Q-linea (QLINEA BTA) Stock Overview

Engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. More details

QLINEA BTA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Revenue is forecast to grow 76.09% per year

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Makes less than USD$1m in revenue (SEK5M)

Shareholders have been substantially diluted in the past year

+ 2 more risks

QLINEA BTA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Q-linea AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Q-linea
Historical stock prices
Current Share Price	SEK 5.76
52 Week High	SEK 6.40
52 Week Low	SEK 2.80
Beta	0.40
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	92.64%

Recent updates

Shareholder Returns

	QLINEA BTA	SE Medical Equipment	SE Market
7D	n/a	2.0%	2.9%
1Y	n/a	-13.2%	2.2%

Return vs Industry: Insufficient data to determine how QLINEA BTA performed against the Swedish Medical Equipment industry.

Return vs Market: Insufficient data to determine how QLINEA BTA performed against the Swedish Market.

Price Volatility

Is QLINEA BTA's price volatile compared to industry and market?
QLINEA BTA volatility
QLINEA BTA Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.5%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.9%
10% least volatile stocks in SE Market	2.9%

Stable Share Price: QLINEA BTA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine QLINEA BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	149	Jonas Jarvius	qlinea.com

Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom. It offers ASTar, an antibiotic susceptibility testing system used for positive blood cultures; and in vitro diagnostics systems for infectious diseases. The company serves healthcare providers.

Q-linea AB (publ) Fundamentals Summary

How do Q-linea's earnings and revenue compare to its market cap?
QLINEA BTA fundamental statistics
Market cap	SEK 869.27m
Earnings (TTM)	-SEK 249.20m
Revenue (TTM)	SEK 5.33m

163.2x

P/S Ratio

-3.5x

P/E Ratio

Is QLINEA BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
QLINEA BTA income statement (TTM)
Revenue	SEK 5.33m
Cost of Revenue	SEK 12.19m
Gross Profit	-SEK 6.86m
Other Expenses	SEK 242.34m
Earnings	-SEK 249.20m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Nov 02, 2023

Earnings per share (EPS)	-2.13
Gross Margin	-128.74%
Net Profit Margin	-4,678.07%
Debt/Equity Ratio	264.1%

How did QLINEA BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/07/30 21:01
End of Day Share Price	2023/07/27 00:00
Earnings	2023/06/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Q-linea AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kristofer Liljeberg-Svensson	Carnegie Investment Bank AB
Ulrik Trattner	Carnegie Investment Bank AB
Mats Hyttinge	Redeye

Q-linea AB (publ)OM:QLINEA BTA Stock Report